Current Opinion in Oncology最新文献_第8页

Reirradiation in recurrent glioblastoma. 复发性胶质母细胞瘤的再照射治疗。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-09-03 DOI: 10.1097/CCO.0000000000001192

Tomas Kazda, Lucie Hnidakova, Giuseppe Minniti

{"title":"Reirradiation in recurrent glioblastoma.","authors":"Tomas Kazda, Lucie Hnidakova, Giuseppe Minniti","doi":"10.1097/CCO.0000000000001192","DOIUrl":"10.1097/CCO.0000000000001192","url":null,"abstract":"Purpose of review: Reirradiation has emerged as a potentially valuable treatment strategy for recurrent glioblastoma, a disease characterized by inevitable local progression despite aggressive multimodal first-line therapy. Recent advances in radiotherapy techniques, improved patient selection, and evolving systemic treatment combinations have renewed clinical interest in this approach. This is reflected by recent publication of the first international consensus guidelines (ESTRO/EANO) and the initiation of an European phase III randomized trial on reirradiation of patients with recurrent glioblastoma.Recent findings: Retrospective and early-phase prospective studies have demonstrated that reirradiation is feasible and well tolerated in selected patients, with median overall survival ranging from 7 to 13 months. The ESTRO/EANO guidelines on reirradiation of glioma provide standardized recommendations for patient selection, dose constraints, and target volume delineation. Meta-analyses suggest improved outcomes when reirradiation is combined with systemic therapies, such as bevacizumab or lomustine. The phase III EORTC-2227-BTG (LEGATO) trial will provide definitive data on survival benefit.Summary: Reirradiation is gaining acceptance as a palliative yet potentially impactful treatment for recurrent glioblastoma. While current evidence supports its use in selected cases, results from ongoing phase III LEGATO trial will determine its future role in standard care and inform evidence-based clinical decision-making.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"580-588"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145243935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interpreting the clinical outcomes to date for AML-directed CAR T cell therapies. 解释迄今为止aml靶向CAR - T细胞疗法的临床结果。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-08-06 DOI: 10.1097/CCO.0000000000001186

Allison J Li, Jae H Park

{"title":"Interpreting the clinical outcomes to date for AML-directed CAR T cell therapies.","authors":"Allison J Li, Jae H Park","doi":"10.1097/CCO.0000000000001186","DOIUrl":"10.1097/CCO.0000000000001186","url":null,"abstract":"Purpose of review: Chimeric antigen receptor (CAR) T therapies hold potential as a new therapeutic approach for relapsed/refractory acute myeloid leukemia (R/R AML), but development has been challenging due to difficulty identifying the optimal targeting antigen. AML exhibits heterogenous and overlapping antigen expression with normal hematopoietic cells, raising concerns for poor efficacy and on-target/off-tumor hematotoxicity. However, it is not clear that these concerns have been fully borne out in available clinical data. Here, we review clinical studies of AML CAR T therapies with a focus on critically evaluating efficacy and toxicities.Recent findings: Encouraging responses have been reported in a notable proportion of patients in published trials, especially when taking into consideration that patients have treatment-resistant disease after multiple lines of therapy. Rates of cytopenias after AML CAR T therapies vary and there are insufficient data to delineate whether they are due to on-target toxicity or off-target effects such as low marrow reserve and myelosuppressive inflammatory sequelae.Summary: These studies highlight the need for continued optimization of CAR T design and treatment strategies to enhance efficacy and reduce toxicities in AML. Further studies are needed to better understand the frequency/severity of cytopenias after AML CAR T therapies and to clarify the underlying on-/off-target mechanisms.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"658-668"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Open questions on vorasidenib. 关于vorasidenib的公开问题。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-09-12 DOI: 10.1097/CCO.0000000000001193

Antoine Seyve, François Ducray

{"title":"Open questions on vorasidenib.","authors":"Antoine Seyve, François Ducray","doi":"10.1097/CCO.0000000000001193","DOIUrl":"10.1097/CCO.0000000000001193","url":null,"abstract":"Purpose of review: Vorasidenib has demonstrated efficacy in isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas that do not require immediate oncological treatment. Here, we summarize open questions regarding its long-term benefit, its optimal use in IDH-mutant grade 2 gliomas as well as its potential use in grade 3 and 4 IDH-mutant gliomas.Recent findings: In IDH-mutant grade 2 gliomas, vorasidenib may act as a differentiation therapy. Updated results from the INDIGO trial suggest an additional effect on seizure control. Volumetric analysis and amino acid PET imaging may improve response assessment. However, long-term follow-up and new clinical trials will be needed to determine whether first-line vorasidenib preserves cognition, quality of life and improves overall survival. Since contrast-enhancement rather than histological grade appears to be more closely associated with disease control, selected grade 3 IDH-mutant gliomas might also benefit from first-line vorasidenib. Ongoing trials are evaluating vorasidenib as maintenance therapy after radiochemotherapy, and in association with chemotherapy and different immunotherapies.Summary: While vorasidenib is becoming the first-line treatment in the majority of IDH-mutant grade 2 gliomas, we are progressively learning how it works, how it should be used and in which contexts beyond grade 2 IDH-mutant gliomas it could be beneficial.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"589-594"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monitoring serum estradiol in premenopausal women with hormone receptor-positive breast cancer on adjuvant LHRH agonists. 使用辅助LHRH激动剂监测激素受体阳性乳腺癌绝经前妇女血清雌二醇。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-09-03 DOI: 10.1097/CCO.0000000000001191

Carmine Valenza, Julian D Etessami, Elisabetta Munzone, Gabriella Pravettoni, Giuseppe Curigliano, Dario Trapani

{"title":"Monitoring serum estradiol in premenopausal women with hormone receptor-positive breast cancer on adjuvant LHRH agonists.","authors":"Carmine Valenza, Julian D Etessami, Elisabetta Munzone, Gabriella Pravettoni, Giuseppe Curigliano, Dario Trapani","doi":"10.1097/CCO.0000000000001191","DOIUrl":"10.1097/CCO.0000000000001191","url":null,"abstract":"Purpose of review: To review the current evidence and inform clinical guidance on the implications of incomplete ovarian function suppression (OFS), the utility of serum estradiol (E2) monitoring, and appropriate management strategies in premenopausal women with early breast cancer (eBC) receiving adjuvant luteinizing hormone-releasing hormone agonist (LHRHa)-based therapy for OFS.Recent findings: A universally accepted definition of incomplete OFS is currently lacking. Although biologically it is plausible that incomplete OFS may compromise the efficacy of endocrine therapy, its actual impact on clinical outcomes remains unclear. Currently, the reliability of E2 monitoring is limited by considerable variability in assay methods and reference ranges, raising concerns about its analytical validity. Notably, in a recent international survey of 205 oncologists managing patients with eBC, 43% reported routinely and 27% occasionally assessing E2 levels in premenopausal patients treated with LHRHa, suggesting inconsistent clinical practice. Standard immunoassays were the most frequently used (65%). However, interpretation of E2 values and subsequent management decisions varied widely, highlighting the absence of standardized clinical guidelines.Summary: Although not currently supported by high-level evidence, serum E2 monitoring is widely adopted in clinical practice. Prospective studies and evidence-based recommendations are urgently needed. Emerging strategies to overcome incomplete OFS include LHRH antagonists (e.g., degarelix) and oral SERDs.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"546-551"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Curative strategies for high-risk acute promyelocytic leukemia. 高危急性早幼粒细胞白血病的治疗策略。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-09-24 DOI: 10.1097/CCO.0000000000001171

Kuo-Kai Chin, Martin S Tallman

{"title":"Curative strategies for high-risk acute promyelocytic leukemia.","authors":"Kuo-Kai Chin, Martin S Tallman","doi":"10.1097/CCO.0000000000001171","DOIUrl":"10.1097/CCO.0000000000001171","url":null,"abstract":"Purpose of review: Patients with acute promyelocytic leukemia (APL) who present with leukocytosis are considered high-risk due to lower relapse-free survival when treated with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy. The discovery and incorporation of arsenic trioxide (ATO) in therapeutic regimens for high-risk patients have led to improved survival, but there is no consensus on the optimal treatment approach. This review addresses reduction in early death and explores questions of regimen selection, including the choice of induction, consolidation, and maintenance, as well as the use of prophylactic adjunctive therapies, while examining clinical trial and real-world evidence.Recent findings: ATRA-ATO combined with idarubicin (IDA) or gemtuzumab ozogamicin are highly effective compared to ATRA-IDA-based chemotherapy in clinical trials and real-world studies. Improved survival and early death reduction can be seen in the randomized controlled APOLLO study and in data from the recently published HARMONY and HERO analyses.Summary: ATRA-ATO-based combinations, including ATRA-ATO-IDA and ATRA-ATO-GO, are current standards of care in high-risk APL. Further studies should seek to clarify the choice between these and other regimens and to more clearly show the benefit of maintenance therapy and of additional therapies such as for differentiation syndrome and CNS prophylaxis with these highly effective induction/consolidation regimens.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"633-640"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-proxy agreement on health-related quality of life assessment in cancer patients. 癌症患者健康相关生活质量评估的患者代理协议

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1097/CCO.0000000000001189

Josien C C Scheepens, Florien W Boele, Johan A F Koekkoek

{"title":"Patient-proxy agreement on health-related quality of life assessment in cancer patients.","authors":"Josien C C Scheepens, Florien W Boele, Johan A F Koekkoek","doi":"10.1097/CCO.0000000000001189","DOIUrl":"10.1097/CCO.0000000000001189","url":null,"abstract":"Purpose of review: The aim of this study was to examine the role of proxy-reported outcomes in oncology, particularly in neuro-oncology, where cognitive impairment and disease progression often limit patients' ability to self-report. With increasing emphasis on patient-centered care and regulatory requirements for clinical outcome assessments (COAs), it is essential to understand when and how proxy reports can substitute or complement patient-reported outcomes (PROs), particularly in the assessment of health-related quality of life (HRQoL).Recent findings: Use of proxy-reported outcomes in cancer clinical trials is common. Proxy reports can help reduce missing data and selection bias by replacing PROs in patients with a poor health condition. However, studies consistently show poor to moderate agreement between patient and proxy reports of HRQoL outcomes, with the lowest congruence in less observable areas such as emotional functioning. Most proxy reports rely on PRO instruments not validated for proxy use, and heterogeneity in statistical methods, proxy selection, and proxy instruction further complicates interpretation.Summary: While proxy-reported outcomes should not replace PROs when patients can self-report, they offer valuable insights when self-report is not feasible. When standardized methods are followed, such as using validated instruments and clearly defining the reporting perspective, proxy reports can serve as a useful alternative in clinical trials and clinical practice.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"603-610"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-risk smoldering myeloma - a case for early intervention? 高危阴燃性骨髓瘤——早期干预的案例？

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-08-26 DOI: 10.1097/CCO.0000000000001182

Anupama Krishnamoorthi, Rohit Vijjhalwar, Ananya Kannan, Karthik Ramasamy

{"title":"High-risk smoldering myeloma - a case for early intervention?","authors":"Anupama Krishnamoorthi, Rohit Vijjhalwar, Ananya Kannan, Karthik Ramasamy","doi":"10.1097/CCO.0000000000001182","DOIUrl":"10.1097/CCO.0000000000001182","url":null,"abstract":"Purpose of review: Smoldering myeloma (SMM) is an asymptomatic precursor condition of multiple myeloma (MM) with a prevalence of about 0.5% in those aged >40 years age. While the current standard of care is active surveillance, there is a growing interest to determine the effectiveness of early intervention in this condition. This review discusses the contemporary trials focussed on treating SMM and the case for additional data in this space.Recent findings: It is imperative to note that the risk stratification for SMM has constantly evolved over time. A proportion of patients with SLiM-CRAB [≥60% bone marrow plasma cells (BMPCs), free light chain ratio (sFLC-ratio) ≥100, and >1 MRI-defined ≥5 mm focal bony lesion, hypercalcemia, renal insufficiency, anaemia, lytic bone lesions], who were classified as high-risk-SMM in the past, have now been classified as MM, based on the IMWG-2014 diagnostic criteria. Current research on SMM risk stratification is focussed on developing models based on longitudinal trends, rather than single-point measures. Earlier trials were studying disease control strategy, working towards delaying disease progression. As the results were promising, currently, there are more trials utilizing intensive treatment approaches aiming at cure to eradicate disease clone (achieving sustained MRD negativity). Further ongoing trials, are attempting to refine disease control strategy and utilize immunotherapies.Summary: We need more high-quality evidence in post-SLiM-CRAB SMM cohort to better identify the subset of patients most likely to benefit from early intervention. Treatment approaches should be refined considering patient preferences and maintaining quality of life (QoL).","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"650-657"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of response to CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a consolidated review. CD19嵌合抗原受体t细胞治疗对大b细胞淋巴瘤反应的预测因素：综合综述

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-09-03 DOI: 10.1097/CCO.0000000000001188

Ori Ben Valid, Roni Shouval

{"title":"Predictors of response to CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a consolidated review.","authors":"Ori Ben Valid, Roni Shouval","doi":"10.1097/CCO.0000000000001188","DOIUrl":"10.1097/CCO.0000000000001188","url":null,"abstract":"Purpose of review: CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has transformed outcomes for relapsed/refractory large B-cell lymphoma (LBCL), yet nearly half of treated patients relapse, and toxicities remain frequent. A deeper understanding of response predictors is urgently needed to guide patient selection, treatment optimization, and development of rational combination strategies.Recent findings: Emerging data reveal that response to CAR-T therapy is shaped by patient-specific, tumor-intrinsic, and treatment-related factors. Clinical variables such as age, performance status, inflammation, and microbiome composition influence efficacy. Tumor burden, disease distribution, histologic subtype, and genomic alterations correlate with resistance. Treatment factors, including bridging strategies, lymphodepletion regimen, and CAR-T product design, affect expansion, persistence, and clinical outcomes. Novel insights from immune profiling, radiomics, and single-cell transcriptomics offer further granularity and predictive potential.Summary: Predictors of CAR-T response span diverse biological and clinical domains and are increasingly actionable. Integrating multimodal biomarkers into routine workflows can personalize care and improve outcomes. Prospective validation, real-time monitoring, and adaptive trial designs are essential next steps toward precision CAR-T therapy.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"625-632"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13391963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circulating tumor DNA in early-stage triple-negative breast cancer: clinical landscape and key open challenges. 早期三阴性乳腺癌循环肿瘤DNA：临床前景和关键开放挑战

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-07-16 DOI: 10.1097/CCO.0000000000001180

Pietro De Placido, Heather A Parsons

{"title":"Circulating tumor DNA in early-stage triple-negative breast cancer: clinical landscape and key open challenges.","authors":"Pietro De Placido, Heather A Parsons","doi":"10.1097/CCO.0000000000001180","DOIUrl":"10.1097/CCO.0000000000001180","url":null,"abstract":"Purpose of review: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for noninvasive detection of minimal residual disease (MRD), prognosis, and treatment monitoring in early-stage triple-negative breast cancer (eTNBC), an aggressive subtype with high relapse risk. This review synthesizes the state-of-the-art and the advances in ctDNA technologies and evaluates their clinical relevance across the neoadjuvant, postneoadjuvant, and adjuvant settings.Recent findings: We highlight the most recent (last 18-24 months) key prospective studies demonstrating ctDNA's potential to predict pathological response and recurrence, emphasizing the prognostic value of the ctDNA dynamics and the implications of persistent positivity. We discuss tumor-informed versus tumor-agnostic assays, address challenges in detecting MRD, and explore future directions, including ultrasensitive detection strategies, novel methylation and machine learning-based approaches, and ctDNA-guided therapeutic interventions.Summary: Despite encouraging results, the clinical utility of ctDNA remains unproven due to technical limitations, especially in assay sensitivity, timing of testing, and low ctDNA shedding/high relapse rate in early-stage disease. Randomized trials are essential to confirm the role of ctDNA in guiding treatment de-escalation or escalation, ultimately aiming to personalize care and improve outcomes in patients with eTNBC.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"534-545"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting androgen receptors in patients with metastatic breast cancer. 转移性乳腺癌患者雄激素受体靶向研究

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-09-12 DOI: 10.1097/CCO.0000000000001187

Lorenzo Guidi, Dario Trapani, Giuseppe Curigliano

{"title":"Targeting androgen receptors in patients with metastatic breast cancer.","authors":"Lorenzo Guidi, Dario Trapani, Giuseppe Curigliano","doi":"10.1097/CCO.0000000000001187","DOIUrl":"10.1097/CCO.0000000000001187","url":null,"abstract":"Purpose of review: This review aims to summarize the current clinical evidence and future perspectives on the use of antiandrogen therapies in metastatic breast cancer, focusing on hormone receptor-positive and triple-negative subtypes, expressing androgen receptor (AR). We discuss recent clinical trials evaluating AR-targeted agents and explore mechanisms of resistance and novel therapeutic strategies.Recent findings: Clinical trials of androgen-targeting have shown modest activity in AR-positive metastatic breast cancer, with variable disease control rates and progression-free survival depending on AR expression levels, intrinsic AR-dependency and tumor subtype. Combination therapies targeting AR alongside pathways like CDK4/6 and PI3K/AKT/mTOR appear promising in overcoming therapeutic resistance. New-generation agents, including PROTACs, nonligand-binding domain AR inhibitors and epigenetic modulators offer innovative approaches to target AR signalling.Summary: Despite encouraging preclinical data, antiandrogen therapies have not demonstrated robust strong clinical efficacy in metastatic, AR-positive breast cancer, and their use in the clinical practice is still very limited. Improved patient selection using validated predictive biomarkers is crucial. Combination regimens and next-generation AR-targeting agents represent the future direction to overcome resistance and optimize therapeutic outcomes in AR-driven breast cancers.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"562-569"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0